Cargando…

“This Drug May Work, But Is It Worth the Cost?” Can Comparative Effectiveness Research Help Tame Rising Health Care Costs?

Detalles Bibliográficos
Autores principales:	Brixner, Diana I., Watkins, John B., Oderda, Gary, Sifford-Wilson, S. Monet, Biskupiak, Joseph E., Dunn, Jeffrey D., Holtorf, Anke-Peggy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2012
Materias:	Supplement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437726/ http://dx.doi.org/10.18553/jmcp.2012.18.s5-a.S1

Ejemplares similares

Bringing Liraglutide to Market: A CER Case Study
por: Oderda, Gary, et al.
Publicado: (2012)

Three Perspectives on the Impact of Comparative Effectiveness Research on Decision Making
por: Brixner, Diana I., et al.
Publicado: (2012)

Implementing CER: What Will It Take?
por: Biskupiak, Joseph E., et al.
Publicado: (2012)

Cost Implications of Formulary Decisions on Oral Anticoagulants in Nonvalvular Atrial Fibrillation
por: Biskupiak, Joseph, et al.
Publicado: (2013)

Payer perceptions on the use of economic models in oncology decision making
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Payer perceptions of the use of real-world evidence in oncology-based decision making
por: Brixner, Diana, et al.
Publicado: (2021)

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
por: Ghate, Sameer R., et al.
Publicado: (2011)

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
por: Mistry, Rohit, et al.
Publicado: (2018)

Systematic review on quality control for drug management programs: Is quality reported in the literature?
por: Holtorf, Anke-Peggy, et al.
Publicado: (2009)

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis
por: Rochau, Ursula, et al.
Publicado: (2015)

The cost-effectiveness challenge: is it worth it?
por: Knapp, Martin
Publicado: (2015)

Introduction
por: Brixner, Diana I., et al.
Publicado: (2012)

The Unhidden Cost of Noncompliance
por: Mahoney, John J., et al.
Publicado: (2008)

Patient Perspectives on the Use of Digital Technology to Help Manage Cystic Fibrosis
por: Watanabe, Alexandre H., et al.
Publicado: (2023)

An Economic Analysis: Is Fidaxomicin Worth the Cost?
por: Shah, Hemal, et al.
Publicado: (2014)

Are fishery management upgrades worth the cost?
por: Mangin, Tracey, et al.
Publicado: (2018)

The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis
por: Kane, Sunanda V., et al.
Publicado: (2008)

Managed Care Strategies for Improving Patient Outcomes in Rheumatoid Arthritis
por: Agarwal, Sandeep K., et al.
Publicado: (2011)

Addressing Rising Healthcare Costs with Innovation: A Six-Year Institutional Experience in DIEP Flap Reconstruction
por: Tycher, John, et al.
Publicado: (2023)

Taming the Lion: How Perceived Worth Buffers the Detrimental Influence of Power on Aggression and Conflict
por: Weick, Mario, et al.
Publicado: (2018)

Opioid Dependence: Managing the High Cost of Treatment Failure
por: Jan, Saira A.
Publicado: (2010)

All-Cause and Incremental Per Patient Per Year Cost Associated with Chronic Hepatitis C Virus and Associated Liver Complications in the United States: A Managed Care Perspective
por: McAdam-Marx, Carrie, et al.
Publicado: (2011)

Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States
por: Biskupiak, Joseph E, et al.
Publicado: (2023)

Shifting the Focus From Cost to Value: Key Stakeholder Perspectives
por: Chao, Schumarry H., et al.
Publicado: (2006)

Incorporating Observational Data into the Formulary Decision-Making Process--Summary of a Roundtable Discussion
por: Holtorf, Anke-Peggy
Publicado: (2008)

Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment
por: Panchal, Rupesh, et al.
Publicado: (2023)

173. The Rise Of Acellular Dermal Matrix: Cost Consciousness, Industry Payments, And Publication Productivity
por: Hirpara, Milan M., et al.
Publicado: (2023)

Cost-Benefit Analysis of the LHC to 2025 and beyond: Was it Worth it ?
por: Prof. Florio, Massimo
Publicado: (2015)

Electronic hand hygiene monitoring systems: Not worth the costs
por: Doll, Michelle E., et al.
Publicado: (2022)

Burden of Illness: Costs and Consequences of Our Fragmented Mental Health Care System
por: Arizpe, Michael, et al.
Publicado: (2006)

Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids
por: Harrington, Amanda, et al.
Publicado: (2020)

Mild-to-Moderate Ulcerative Colitis: Your Role in Patient Compliance and Health Care Costs
por: Tindall, William N., et al.
Publicado: (2007)

Evaluating Risks, Costs, and Benefits of New and Emerging Therapies to Optimize Outcomes in Multiple Sclerosis
por: Bandari, Daniel S., et al.
Publicado: (2012)

3. The Rise of Acellular Dermal Matrix: Cost Consciousness, Industry Payments, and Publication Productivity
por: Clark, Robert Craig, et al.
Publicado: (2023)

Sex Is Always Well Worth Its Two-Fold Cost
por: Feigel, Alexander, et al.
Publicado: (2009)

Costs of Treatment after Renal Transplantation: Is it Worth to Pay More?
por: Salamzadeh, Jamshid, et al.
Publicado: (2014)

Intraoperative management of hypoxemia with recruitment maneuvers: are the benefits worth the costs?
por: Grosomanidis, V, et al.
Publicado: (2013)

CERN is hit by rising costs
por: Cartlidge, E
Publicado: (2001)

The rising cost of scientific exploration
Publicado: (2008)

The Rise of Prescription Digital Therapeutics in Behavioral Health
por: Brezing, Christina A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n3ukhulip7j648nkna7qvtgsot